NCT04730947View on ClinicalTrials.gov

Dapagliflozin (DAPA) Effects in HFpEF

PHASE2CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

February 24, 2021

Primary Completion Date

November 17, 2022

Study Completion Date

November 17, 2022

Conditions
Heart Failure With Preserved Ejection Fraction
Interventions
DRUG

Dapagliflozin

10 mg orally once a day

DRUG

Placebo

Taken orally once a day, the placebo looks identical to the study drug but it contains no active ingredient

Trial Locations (1)

55905

Mayo Clinic in Rochester, Rochester

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
lead

Mayo Clinic

OTHER

NCT04730947 - Dapagliflozin (DAPA) Effects in HFpEF | Biotech Hunter | Biotech Hunter